Results 291 to 300 of about 2,548,043 (302)

Profile Drawing Line

Scientific American
openaire   +1 more source

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Lancet, The, 2013
Dieter Hoelzer
exaly  

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Lancet, The, 2014
Edward B Garon, Oscar Arrieta, Keunchil Park   +2 more
exaly  

Anal cancer: Current standards in care and recent changes in practice

Ca-A Cancer Journal for Clinicians, 2015
exaly  

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Lancet, The, 2012
Jeffrey A Cohen, Alasdair J Coles, Douglas L Arnold   +2 more
exaly  

Immune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma

Ca-A Cancer Journal for Clinicians, 2018
exaly  

Preserving Primary Care: the Front Line in the War Against Cancer

Ca-A Cancer Journal for Clinicians, 2007
exaly  

Profile sheet to accompany sheet 10 -- profile on north building line (see plan)\, profile on center line\, profile on south building line : Sheet no. 11.

2019
  +4 more sources

First‐line low‐dose morphine is better for the control of moderate cancer pain than weaker opioids

Ca-A Cancer Journal for Clinicians, 2016
exaly  

Three dimensional line profile analysis

2023
openaire   +1 more source